This Regulation organises around a small set of legal and operational concepts that convert the Act’s framework into day-to-day obligations. Key concepts are defined either expressly in the Regulation or by reference to the Act, and they determine legal consequences.

• Precursors and apparatus. The Regulation explicitly specifies which chemical substances are precursors and which pieces of equipment are drug manufacture apparatus for the Act, s 24A, by listing them in Schedules 1-3 (s 4(1)-(2), Schedules 1-3). Schedule 4 sets out particular substances together with threshold quantities prescribed for the Act, s 24B (s 4(3)-(4); Schedule 4).
• Schedule categories. The Regulation separates items into Schedule 1 (highest supplier controls), Schedule 2 and Schedule 3 (apparatus) for the purposes of imposing progressively different supplier obligations (ss 5-7). The instrument also defines the term Schedule 1 precursor and Schedule 2 precursor by reference to Schedule contents and exclusions for preparations, salts, isomers, etc (ss 5(7), 6(4)).
• Supplier duties and end user declaration. Suppliers of Schedule 1 items must satisfy a tripartite set of conditions before supply: the receiver must have an account with the supplier and payment must go through that account, the receiver must provide an end user declaration at least 24 hours before supply, and the receiver must provide proof of identity at least 24 hours before supply (s 5(1)). For Schedule 2 precursors and Schedule 3 apparatus suppliers must obtain proof of identity and either have account-based payment or receive an end user declaration (ss 6(1), 7(1)). The Regulation defines what an end user declaration must contain in each case (ss 5(7), 6(4), 7(4)).
• Proof of identity. The Regulation limits acceptable identity documents for the supplier’s verification to three Australian photographic ID documents: Australian driver licence (with photograph), Australian passport, or Photo Card issued under the Photo Card Act 2005 (s 8).
• Recordkeeping and police inspection. Suppliers must keep records of supplies, end user declarations and authorisations and make them available for police inspection during business hours; retention period is at least two years (ss 5(4)-(5), 6(2)-(3), 7(2)-(3)).
• Evidentiary certificates and prima facie proof. The Regulation creates a regime where certificates produced under specified provisions are prima facie evidence of the matters stated (for example s 11(3) for initial quantity or mass, s 31 for exhibits management system sheets, s 32 for continuity of exhibits). The doctrine applies unless a quantity review order is made in the Act, s 39M, which is expressly noted as an exception (s 11(4)).
• A sample/B sample regime. For specified categories of relevant substances the Regulation requires timely provision of A samples for analysis (s 14). Defendants have a statutory right to request analysis of B samples within a 28 day period after service of the A sample certificate; the defendant bears the cost of that analysis (s 16).
• Chain of custody and security. The Regulation mandates use of approved tamper-evident drug exhibit bags, labelling requirements, dual-key vaults (or approved facilities), and entry of particulars into the NSW Police Force exhibits management system (ss 21-24).
• Analyst roles and certificates. The Regulation defines analyst approval structures and what analysts may test and certify, including authority for FASS directors to order destruction of sample material (ss 10, 17-18, 26).
• Exemptions. Part 4 prescribes targeted exemptions from the Act’s possession and supply prohibitions to enable official duties or specified public health services, with scope and limits defined in the text (ss 34-38).

These main concepts form the operational vocabulary for suppliers, police, analysts and courts. They define who must do what, what documents must look like, how long records must be kept, and when evidentiary presumptions will apply in prosecutions.

The Regulation creates obligations and privileges that affect a range of private and public actors. Below is an itemised mapping of affected parties with the provisions that bind or enable them.

• Suppliers of chemicals and equipment. Any person supplying items listed in Schedule 1, Schedule 2 or Schedule 3 is directly affected because the Regulation prescribes pre-sale conditions, storage duties, recordkeeping, and availability of documents for police inspection (ss 5-7). Corporations face higher maximum penalties than individuals for breaches (ss 5-7).
• Receivers or customers. Persons purchasing listed precursors or apparatus must either hold an account with the supplier for account-based payments or complete an end user declaration. For Schedule 1 items, declarations and identity must be provided at least 24 hours before supply (s 5). Receivers are the parties whose intended use is disclosed in declarations (ss 5(7), 6(4), 7(4)).
• Pharmacists and supervised staff. Pharmacists and persons acting under their supervision are expressly exempt to the extent necessary to possess and distribute syringes and provide hygienic-use information under the Act, s 11, 19 and 20 (s 38). This affects pharmacy practice in relation to needle and syringe services.
• Participants in needle and syringe programs. Persons participating in designated programs listed in the Ministry of Health document are exempt to the extent necessary to possess and distribute syringes and communicate location and hours information (s 37).
• NSW Police Force members and qualified police officers. Police members have detailed duties under the chain of custody and exhibits management provisions: recording initial mass or quantity and producing certificates, sealing and labelling drug exhibit bags, entering particulars into the exhibits management system, and managing transport and storage (ss 11, 21, 24). Certain police officers designated as Scene of Crime Officers receive a specified exemption to enable their functions (s 34). Qualified police officers make a range of decisions including arranging B sample analysis and ordering destruction of material after proceedings (ss 16, 26).
• Analysts and FASS. Analysts tasked with analysis must perform identification, quantification and, where prescribed, purity testing; they issue certificates that operate as prima facie evidence (ss 17-18). The director of FASS or delegate can order destruction of retained non-needed sample material (s 26). The Regulation recognises analysts from corresponding State or Territory laws as analysts for the Act, s 3(1) (s 39).
• Qualified plant identifiers. Persons approved by the Secretary of Regional NSW to identify prohibited plants are brought into the chain of custody requirements for plant exhibits and can be given access for identification purposes (ss 10, 12, 27).
• Approved couriers and persons engaged under contract. Approved couriers may transport drug exhibit bags for analysis (s 20(2)). Persons contracted by police to transport, store or destroy cannabis are granted exemptions from specified offences but only to the extent needed to perform those contract duties; the exemption also extends to their employees (s 36).
• Defendants and accused persons. Legal rights and obligations in proceedings are affected: defendants receive copies of initial quantity certificates (s 11(2)), can request B sample analysis within 28 days of an A sample certificate (s 16), and can be required to pay for B sample analysis (s 16(7)). The Regulation also structures prima facie evidence via certificates, while explicitly carving out exceptions such as quantity review orders (s 11(3)-(4)).
• The Director of Public Prosecutions. The Regulation requires a later analyst, if they find significant differences between certificates, to forward all certificates relating to the drug exhibit to the DPP (s 19).
• Law Enforcement Conduct Commission officers. Officers acting under Part 6 of the LECC Act are exempted to the extent necessary to exercise their powers (s 35).

The Regulation therefore affects both private commercial actors (suppliers, pharmacists, couriers, contracted service providers) and public law enforcement and forensic actors (police, analysts, FASS, DPP). The obligations are operational and granular: they govern pre-sale customer verification, physical security, record creation and retention, evidentiary certificate formats and retention, sample splitting and B sample access, and criteria and processes for destruction and transport. The scope of exemptions is narrowly defined in the text and tied to functional need.

This Regulation creates specific enforceable duties on suppliers, law enforcement and analysts, and confers formal rights on defendants and certain public officers. Below are the principal duties and rights with direct statutory citations.

Supplier duties and recordkeeping

• Schedule 1 suppliers. Must not supply a Schedule 1 precursor unless the receiver has an account with the supplier and payment is made through that account, has provided an end user declaration at least 24 hours before the supply, and has provided proof of identity at least 24 hours before supply (s 5(1)). Suppliers must store Schedule 1 precursors to prevent access by unauthorised persons, record name, quantity and date of supply, make end user declarations and records available for police inspection during business hours and keep them for at least two years (ss 5(2)-(5)). Suppliers who authorise persons in writing to access Schedule 1 precursors must make that authorisation available for inspection and retain a copy for at least two years after it ceases (s 5(3)).
• Schedule 2 and Schedule 3 suppliers. Must obtain proof of identity from receivers and either require account-based payment or an end user declaration before supply (ss 6(1), 7(1)). Must keep records of the name and quantity supplied and date of supply, make declarations and records available for police inspection and retain them for at least two years (ss 6(2)-(3), 7(2)-(3)).
• End user declaration content. The Regulation prescribes the contents of end user declarations for Schedule 1, 2 and 3 supplies. Declarations must identify the receiver, specify identity proof details, specify the name and quantity of the item to be supplied, the intended use, and, for Schedule 1 only, the proposed date of supply (ss 5(7), 6(4), 7(4)).

Identity verification

• Proof of identity is limited to an Australian driver licence with photo, an Australian passport, or a Photo Card under the Photo Card Act 2005 (s 8).

Penalties and executive liability

• The supplier provisions carry maximum penalties for corporations of 100 penalty units for a first offence and 150 penalty units for second or subsequent offences, and for individuals 30 penalty units for a first offence and 50 penalty units for subsequent offences (ss 5-7). Offences against ss 5-7 are prescribed as offences to which the Act, s 43A applies (s 9), so executive liability rules in the Act will be engaged.

Police and analyst duties for exhibits and analysis

• Initial recording and certificates. As soon as practicable after a relevant substance first comes into police custody and before sample taking, an approved member must record the initial quantity or mass or provide the substance to an analyst to do so, and the member or analyst must produce a certificate stating that initial quantity or mass and serve a copy on the defendant in all proceedings relating to the substance (s 11(1)-(2)).
• Prima facie status and exceptions. Production of a certificate purporting to be signed by an approved member or analyst is prima facie evidence of the initial quantity or mass and matters stated in it (s 11(3)), except if a quantity review order is made under the Act, s 39M, in which case subsection (3) does not apply (s 11(4)).
• Plant identification. For plant exhibits, an analyst or a qualified plant identifier must be given access to an amount sufficient for identification as soon as practicable (s 12).
• Sample splitting and A samples. For Schedule 9 substances, psychoactive substances and prohibited drugs at or above traffickable quantity, an A sample sufficient for analysis must be provided to an analyst as soon as reasonably practicable (s 14(1)-(2)).
• B sample rights. Defendants may request a B sample analysis within 28 days from service of an A sample certificate. The request can specify a witness or a particular analyst of an approved class. The police must arrange for sufficient B sample material to be analysed and the analyst must provide results to the police officer and the defendant. The cost of B sample analysis is paid by the defendant (s 16).
• Analyst functions. Analysts may analyse to determine whether a substance is a prohibited drug, Schedule 9 or psychoactive substance, and if so to identify it and determine quantity or mass. For prohibited drugs at least commercial quantity, analysts may also determine purity if reasonably practicable. Analysts produce certificates under the Act, s 43(1) containing these matters (ss 17-18).
• Significant variations. If two or more analysts’ certificates concerning the same exhibit differ and a later analyst considers the difference significant, the later analyst must immediately forward all certificates to the DPP (s 19).
• Transport and courier exemptions. Approved members must provide the relevant substance to an analyst for analysis, but transport to qualified plant identifiers or analysts may be performed by an approved courier if the substance is in a drug exhibit bag. Approved couriers transporting or delivering in accordance with the Act or this Part are exempt from possession or supply offences to the extent necessary to enable delivery or transport (s 20).
• Security, labelling and management. Drug exhibit bags must be used, sealed and labelled in an approved way with specified label content and signature, stored in locked dual-key vaults or approved facilities unless in transit, and particulars must be entered into the NSW Police Force exhibits management system as soon as practicable (ss 21-24).

Rights conferred

• Defendants have rights to be served with initial quantity certificates in all proceedings relating to the relevant substance (s 11(2)), to request B sample analysis within 28 days after an A sample certificate is served (s 16(3)), to specify witnesses or analysts in connection with B sample analysis (s 16(4)), and to receive B sample analysis results (s 16(6)).
• Certain public officers have exemptions to enable official duties: Scene of Crime officers, LECC officers, contracted cannabis transport/storage/destroy providers, needle and syringe program participants, and pharmacists acting in the ordinary course of their profession receive specified exemptions from Act provisions to the extent necessary to carry out their functions (Part 4, ss 34-38).

The Regulation therefore creates a layered compliance landscape combining supplier duties, police procedural duties, forensic laboratory duties, evidentiary presumptions and limited statutory rights for defendants. Many duties are procedural and documentary in form, aiming to generate traceable records and preserve chain of custody.

The Regulation prescribes penalties for supplier breaches, integrates with Act compliance mechanisms and contains multiple enforcement points where police can inspect, certify or demand compliance. The enforcement architecture is both administrative and criminal.

Specified penalties

• Supplier offences under ss 5-7. Each of the supplier obligation provisions for Schedule 1, Schedule 2 and Schedule 3 items carries maximum penalties expressly stated in the Regulation. For corporations the maxima are 100 penalty units for a first offence and 150 penalty units for a second or subsequent offence. For individuals the maxima are 30 penalty units for a first offence and 50 penalty units for second or subsequent offences (ss 5-7).
• Executive liability. The Regulation prescribes offences under ss 5-7 as offences to which the Act, s 43A applies (s 9). That imports the Act’s executive liability framework into these supplier offences. The text of the Act is not reproduced here, but the Regulation explicitly ties these offences to the Act’s executive liability machinery.

Police inspection and administrative enforcement

• Inspection rights. Suppliers must make available, during business hours and on request by a police officer, end user declarations, records of supply and written authorisations to access Schedule 1 precursors (ss 5(3), 5(5), 6(3), 7(3)). Those records must be kept for at least two years. These inspection powers enable on-site administrative enforcement by police.
• Exhibits management system. Police are required to enter particulars of relevant substances into the NSW Police Force exhibits management system and to update it upon opening or change in identity or location. The system produces exhibit detail sheets which, if certified as issued under the system, operate as prima facie evidence of the listed dealings (ss 24, 31). This elevates the exhibits management system into an evidentiary tool that supports prosecutions.
• Certificates as evidence. The Regulation provides that certificates purporting to be signed by approved members or analysts are prima facie evidence of initial quantity or mass and the matters stated in them, and that continuity certificates are prima facie evidence the retained relevant substance is the same as that analysed (ss 11(3), 32). The Regulation also states that certificates need not be supported by proof of the signature, appointment or approval of the person purporting to sign (s 33). These provisions lower the evidential threshold prosecutors must meet and shift the burden to defendants to challenge such certificates through specific mechanisms such as quantity review orders under the Act, s 39M.
• Significant variations reporting. The Regulation requires a later analyst who considers differences between analyst certificates to be significant to immediately forward all certificates to the DPP (s 19). This creates an internal reporting obligation that routes potential evidentiary inconsistencies to prosecutorial review.
• B sample process and cost-shifting. Defendants can request B sample analysis, but the Regulation requires that the cost of that analysis be paid by the defendant (s 16(7)). This imposes a financial barrier to independent verification that may affect exercise of the right.

Destruction safeguards and accountability

• Destruction orders. Only specified persons may order destruction: directors of FASS or delegates can order destruction of parts of samples not required for analysis and of samples for which certificates have been given (s 26(1)). Qualified police officers can order destruction of retained parts for which analysis is not carried out, after the end of all relevant proceedings (s 26(2)). Prior to destruction, an inspector must inspect the drug exhibit bag and determine whether it has been opened or tampered with since sealing (s 28). The actual destruction must occur in the presence of an inspector, an independent witness and a member capable of identifying the exhibit (s 29). These layered checks operate as safeguards but rely on internal police processes and FASS delegation.
• Exemptions. The Regulation grants narrow exemptions from certain Act offences for various government and health-related actors (Part 4). These do not create new enforcement mechanisms but limit the scope of criminal liability for specified conduct.

Practical enforcement features and thresholds

• Identity document limitation. Suppliers may only accept three narrowly specified forms of photographic identity (s 8). This makes noncompliant recordkeeping and supply readily challengeable in enforcement inspections.
• Record-retention timeframes. The two year retention requirement for supplier records and authorisations establishes a fixed temporal window in which police can audit past supplies (ss 5(3)-(5), 6(3), 7(3)).
• Integration with Act processes. Several enforcement features explicitly interact with Act processes. For example, certificates are prima facie unless a quantity review order under Act, s 39M is made (s 11(4)). Also, approved couriers are granted limited exemptions for possession or supply offences for transportation in accordance with the Act or this Part (s 20(3)).

Enforcement risk allocation

• The Regulation positions police as the primary enforcer through inspection powers, custody of exhibits and certification duties. Analysts and FASS directors have delegated operative functions affecting preservation and destruction of scientific material. Suppliers carry criminal risk through statutory penalties and inspection obligations. Defendants’ procedural rights are constrained by deadlines and cost-allocation for B sample analysis, and by the prima facie value attached to certificates.

Collectively, the Regulation creates an enforcement matrix that emphasises documentary compliance and chain of custody. The legal instruments for enforcement are criminal penalties for suppliers, administrative inspection powers, and evidentiary presumptions in prosecutions supported by certificates and the exhibits management system.

The Regulation frequently cross-references and operates in tandem with the Act and certain other State Acts. The interaction is both definitional and operational.

Primary interaction with the Drug Misuse and Trafficking Act 1985

• Statutory purpose. The Regulation implements and operationalises multiple provisions of the Act. It specifies which substances and apparatus are precursors and drug manufacture apparatus for the purposes of Act, s 24A (s 4). It prescribes quantities for the purposes of Act, s 24B via Schedule 4 (s 4(3)-(4)). It also implements procedures for dealing with exhibits and analysis under Act, s 39D (Part 3).
• Evidentiary integration. The Regulation sets out certificates and evidentiary presumptions to be used in proceedings under the Act, including prima facie evidentiary value of analyst and management system certificates; it explicitly applies to proceedings under the Act (s 30). It also notes exceptions where Act processes control evidential effect, for example the quantity review order under Act, s 39M which displaces the prima facie rule in s 11(3).
• Offence and liability framework. The Regulation prescribes certain offences as those to which the Act’s executive liability regime (Act, s 43A) applies (s 9). This integrates the administrative enforcement machinery of the Act with the Regulation’s supplier offences.

Cross references to other State Acts and Commonwealth law

• Interpretation and commencement acts. The Regulation acknowledges that interpretation is affected by the Act and the Interpretation Act 1987 (s 3 note). Its commencement is governed by the Subordinate Legislation Act 1989 which effected repeal of the 2011 Regulation (s 2 note).
• Therapeutic goods and poisons laws. The Regulation provides an express carve-out for supply of Ephedrine, Phenylpropanolamine or Pseudoephedrine when supplied for therapeutic use in accordance with the Poisons and Therapeutic Goods Act 1966 and its regulations and applicable Commonwealth therapeutic goods laws (s 5(6)). This creates an interaction where suppliers complying with those therapeutic goods regimes are exempted from certain Reg duties for those substances.
• Transport and photo ID regimes. Proof of identity references are linked to the Road Transport Act 2013 definition of Australian driver licence and the Photo Card Act 2005 for Photo Cards (s 8). These cross-references determine the universe of acceptable photographic identity documents.
• Law Enforcement Conduct Commission Act 2016. The Regulation grants exemptions to officers of the LECC in relation to Act offences to the extent necessary for LECC functions, and defines officer by reference to the LECC Act, Part 6 (s 35).
• FASS and laboratory governance. The Regulation uses the Forensic and Analytical Science Service of NSW Health Pathology (FASS) as an institutional actor (defined in s 3), giving the director of FASS explicit powers to order destruction of non-essential sample material (s 26). This embeds FASS within the Act’s forensic regime.

Operational interlocks and potential friction points

• Overlap with therapeutic regulation. The exemption for therapeutic supply of certain ephedrine-type substances means suppliers who are also authorised therapeutic goods suppliers must ensure compliance with the Poisons and Therapeutic Goods Act and Commonwealth therapeutic goods laws to rely on the exemption (s 5(6)). Suppliers operating across retail/therapeutic contexts must manage dual compliance regimes.
• Interface with prosecutorial processes. The Regulation routes significant laboratory variations directly to the DPP (s 19). That creates an operational dependency between analysts and the prosecutorial decision-making apparatus in the Act.
• Evidence and appeal processes under the Act. The Regulation’s heavy reliance on certificates as prima facie evidence is tempered by references to Act processes such as quantity review orders and the broader Part 3A evidentiary regime. Courts will therefore resolve disputes by applying both the Regulation’s evidentiary presumptions and the Act’s procedural remedies.
• Interaction with contracted service providers. The Regulation exempts contracted persons engaged to transport, store or destroy cannabis to the extent necessary to perform those functions (s 36). Contracts granting such roles must be structured to ensure the conduct remains within the scope of the exemption and consistent with the Act’s requirements.
• Exhibits management system integration. The Regulation makes the NSW Police Force exhibits management system an evidentiary tool through certifiable exhibit detail sheets (ss 24, 31). That interlocks policing technology and prosecutorial proof, potentially raising questions about system access, data integrity and defence rights to audit the system entries.

Taken together, the Regulation is not an isolated instrument. It embeds the forensic and precursor control regimes within the Act’s procedural and offence frameworks, and it explicitly references and defers to several other State and Commonwealth laws where overlap occurs. The primary legal relationship is direct implementation of the Act’s Part 3A and the precursor provisions in s 24A and s 24B.

The Regulation’s text provides limited but clear information about its enactment and repeal history and preservation of prior rights.

• Commencement and replacement. The Regulation commences on 1 September 2021 and was required to be published on the NSW legislation website (s 2). The regulation expressly replaces the Drug Misuse and Trafficking Regulation 2011, which is repealed on 1 September 2021 by the Subordinate Legislation Act 1989, s 10(2) (s 2 note).
• Savings provision. The Regulation contains an express savings clause stating that an act, matter or thing that, immediately before repeal of the 2011 Regulation had effect under that Regulation continues to have effect under the current Regulation (s 41). In practical terms, continuity of existing administrative acts, authorisations or other matters administratively effected under the old Regulation is preserved.
• No further amendments recorded in the instrument text. The text provided does not contain subsequent amendment notes or a schedule of amendments beyond the commencement and savings provisions. Sections throughout reference the Act and other State Acts, but there are no entries in the Regulation itself indicating later amendments or modification dates within the text supplied.

Practical consequences of the recorded history

• One-off consolidation. The 2021 Regulation functions largely as a consolidation and update of the 2011 instrument; it replaces and carries forward existing effects via the savings clause (s 41). Practitioners should verify whether any subsequent amending instruments have been made since commencement by checking the consolidated online version on the NSW legislation website, because the instrument itself does not list post-commencement amendments.
• Transitional continuity. The savings provision reduces the risk of gaps in authorisations, approvals or ongoing administrative processes started under the repealed 2011 Regulation. However, where the 2021 Regulation introduced new duties (for example, precise end user declaration timing for Schedule 1), suppliers and police must ensure current practice aligns with the new text rather than relying on prior practice.
• Delegation and operational rules. Because the Regulation delegates certain functions to FASS directors, qualified police officers and approved members, any internal operational amendments to those delegations or approvals will occur through administrative instruments rather than the Regulation itself. The Regulation’s structure suggests that many day-to-day changes will be managed by police or FASS protocols, facility approvals and the exhibits management system requirements rather than by frequent statutory amendment.

For legal practitioners advising clients, the immediate amendment history is compact: repeal of the 2011 Regulation and commencement of the 2021 Regulation with a savings clause. The regulatory architecture is therefore new as of 1 September 2021; practitioners should cross-check whether there are subsequent amending regulations or administrative instruments (not captured in the text provided) that modify approved lists, exhibits management system requirements or approved person lists.

The text of the Regulation contains no reported litigation history, case citations or judicial interpretations. There are, however, multiple textual hooks and evidentiary presumptions that are likely to be operative in litigation under the Act, and these warrant attention as likely focal points in any future or ongoing disputes.

No cases named or cited

• The Regulation itself does not name or cite any judicial decisions. It establishes statutory evidentiary presumptions and procedures but leaves dispute resolution to the ordinary processes under the Act and the courts. Consequently, any litigation history arising from interpretation or application of these provisions will be found in court judgments rather than in the Regulation.

Likely litigation focal points derived from the text

• Prima facie certificates and quantity review orders. Section 11(3) establishes that certificates purporting to be signed by approved members or analysts are prima facie evidence of initial quantity or mass, but s 11(4) excludes that prima facie effect if a quantity review order is made under Act, s 39M. Courts will be the forum where the scope of prima facie status and the application of quantity review orders are tested. Disputes may focus on the sufficiency of the certificate, the identity and authority of the signatory, and whether a quantity review order applies.
• Continuity and chain of custody. Sections 31-33 create prima facie continuities through exhibit detail sheets and a specified set of certificates. Litigation may engage these provisions by challenging whether the specified certificates were properly produced, or by arguing that gaps or tampering undermine the prima facie continuity. Section 33 removes the need to prove signatures or appointments for the purposes of prima facie certificates, which may shift litigation to substantive challenges about tampering, duplication or variation.
• Significant variations and disclosure. Section 19 requires a later analyst to immediately forward all certificates to the DPP if a significant difference exists. Litigation could address what constitutes a significant variation, whether the forwarding obligation was followed, and the effect of undisclosed variations on the prosecution case.
• B sample analysis and costs. Section 16 gives defendants a right to request B sample analysis within a fixed 28 day window, but it requires the defendant to pay the cost. Litigation may arise over disputes about the sufficiency of the remaining retained material to perform B analysis, timeliness of requests, or disputes about fulfilment of the defendant’s right to elect an analyst or witness.
• Destruction procedures. Sections 26-29 create procedural safeguards around destruction, including inspector inspection and witness requirements. Litigation may occur where defendants allege improper destruction of material, failure to inspect properly, or destruction before completion of relevant proceedings contrary to these provisions.

Practical note for researchers and practitioners

• Absent judicial guidance, the Regulation’s provisions should be treated as creating strong presumptions and administrative obligations that will carry weight in court. Any challenge by a defendant to the prima facie character of certificates or to the sufficiency of chain of custody is likely to require evidence that specific statutory processes were not followed, for example lack of entry into the exhibits management system, absence of required seals or signatures on drug exhibit bags, failure to retain required amounts of sample material, or failure to provide required certificates to defendants.
• To locate litigation history interpreting these provisions, practitioners must search case law databases and courts’ judgments post-dating the Regulation’s commencement. The present text does not supply that history.

In short, the Regulation contains many provisions that will be material in contested proceedings under the Act, but the instrument itself does not record how courts have treated those provisions.

This Regulation contains a number of features that commonly produce compliance pitfalls, operational confusion or unintended costs. The following "gotchas" are drawn from the text and identify concrete mechanisms that might trip up suppliers, police, analysts, contracted providers and defendants.

Strict identity and timing rules for Schedule 1 supplies

• 24 hour advance requirements. For Schedule 1 precursors suppliers must obtain an end user declaration and proof of identity at least 24 hours before supply, and require account-based payment (s 5(1)). Suppliers who treat Schedules 1, 2 and 3 the same risk contravening the tighter Schedule 1 timing rule. The Regulation imposes different timing and documentary requirements across Schedules 1-3 (ss 5-7). Failure to observe the 24 hour rule for Schedule 1 is an offence with specified penalties.

Narrow acceptable identity documents

• Only three accepted forms of photographic ID. The Regulation limits proof of identity to an Australian driver licence with photograph, an Australian passport, or a Photo Card under the Photo Card Act 2005 (s 8). Suppliers accepting other photo IDs (for example foreign passports, student cards, company IDs) risk noncompliance. This is a narrow list and may be operationally inconvenient for purchasers lacking those specific documents.

Recordkeeping and availability to police

• Two year retention and on-demand inspection. Suppliers must keep end user declarations and records for at least two years and make them available for inspection during business hours to a police officer (ss 5(5), 6(3), 7(3)). Practical missteps include failure to index records for easy retrieval, use of accounts that do not track per-supply details, or lack of clear written authorisations for persons allowed to access Schedule 1 precursors (s 5(3)). Suppliers may be liable even if the substantive supply was lawful, where documentary obligations are breached.

Treatment of salts, esters, isomers and preparations

• Exclusion language in Schedule definitions. The definitions of Schedule 1 precursor and Schedule 2 precursor exclude, unless specified in the Schedule, preparations, admixtures, salts, isomers, esters or ethers of listed substances (s 5(7), s 6(4)). This requires careful chemical knowledge to determine whether a delivered product falls within the Schedule. Suppliers and purchasers must be precise about the chemical form; misclassification can produce inadvertent compliance breaches.

B sample timeline and costs

• 28 day and defendant pays. Defendants must request B sample analysis within 28 days of service of an A sample certificate (s 16(3)). The defendant bears the cost of B sample analysis (s 16(7)). This creates tight time pressure and a financial barrier to independent verification. Defendants who fail to request within 28 days lose statutory ability to obtain a B sample analysis under the Regulation.

A sample/B sample sufficiency and required amounts

• Required amount definition. Section 13 defines the required amount to be three times the amount needed for two samples. Analysts, police and defence need to track that the retained bulk and splits are sufficient to permit both A and B sample analytical work. Failure to retain the required amounts could lead to disputes about the defendant’s right to a B sample analysis and potentially to challenges to the sufficiency of evidence.

Prima facie certificates and quantity review order exception

• Certificates are prima facie evidence. Certificates purporting to be signed by approved members or analysts are prima facie evidence (s 11(3)), but this is displaced by a quantity review order under Act, s 39M (s 11(4)). Litigators must be alert to the existence and timing of any quantity review order because it will change the evidentiary landscape.

Significant variations reporting duty

• Analyst’s immediate obligation to DPP. If a later analyst considers differences significant between certificates, that later analyst must forward all certificates to the DPP immediately (s 19). Failure to do so may affect disclosure obligations and prosecutorial decision-making. Analysts and laboratories must have procedures to detect and report material discrepancies quickly.

Destruction procedures and evidence loss

• Timing and witness requirements. Destruction of samples can be ordered by a FASS director or qualified police officer, but destruction requires prior inspection by an inspector and specified witnesses at destruction (ss 26-29). A misstep in following these procedures can produce allegations of evidence destruction. Contracted providers engaged to transport, store or destroy cannabis receive a narrow exemption (s 36) but only to the extent necessary for contract performance; the exemption does not relieve them of procedural duties in the Regulation.

Exemptions that are limited in scope

• Needle and syringe program lists. Exemptions for needle and syringe programs are available only for programs specified in a particular Ministry of Health document (s 37). Practitioners must check whether a particular program is listed in the document referenced, rather than assuming all harm minimisation services are covered.
• Pharmacist exemption scope. Pharmacists are exempt only to the extent necessary to possess and distribute syringes and provide hygienic information in the ordinary course of their profession (s 38). The exemption does not broadly excuse pharmacists from other Act or Regulation duties.

Approved couriers and limited possession exemption

• Courier exemption scope. Approved couriers transporting relevant substances in drug exhibit bags are exempt from the Act’s possession or supply provisions only to the extent necessary to deliver or transport the relevant substance for analysis (s 20(3)). If a courier’s conduct goes beyond delivery or transport, the exemption may not apply.

Administrative reliance on exhibits management system

• System entries as evidence. Exhibit detail sheets certified as issued under the NSW Police Force exhibits management system are prima facie evidence of the dealings listed in the sheet (s 31). Reliance on the system as an evidentiary basis places weight on accurate data input, access control, and audit trails. Errors or gaps in the system may be legally significant.

These are concrete operational points that will cause problems if not attended to. The common theme is procedural exactitude: narrow document lists, strict timing windows, prescribed retention times, and specific witness and inspection requirements. Entities affected must align organisational processes to the Regulation to avoid penal exposure or evidentiary disadvantages.

This section provides a practical compliance checklist and recommended processes derived directly from the Regulation text. It is organised by actor: suppliers, police and exhibits managers, analysts and FASS, couriers and contracted providers, pharmacists and needle and syringe programs, and defendants.

Suppliers of Schedule 1, 2 or 3 items

• Identify catalogue coverage. Map your product catalogue to Schedules 1-3 and Schedule 4 quantities. Confirm product chemical form (preparation, salt, isomer, ester or ether) against Schedule definitions to determine whether the item falls within a Schedule or is excluded (s 4; ss 5(7), 6(4)).
• Account-based payment procedures. For Schedule 1 supplies, ensure the receiver has an account with you and that payment is made through that account before supply (s 5(1)(a)). For Schedules 2 and 3, use account payment as one permitted path to supply when not relying on an end user declaration (ss 6(1), 7(1)).
• End user declaration templates and storage. Implement standardised end user declaration forms that contain the required fields specified in ss 5(7), 6(4) or 7(4) as applicable. For Schedule 1 items, require the end user declaration to be provided at least 24 hours before supply (s 5(1)(b)). Store electronic and paper declarations securely and ensure they are retrievable for police inspection during business hours for at least two years (ss 5(5), 6(3), 7(3)).
• Identity verification. Only accept the three specified forms of photographic ID: Australian driver licence with photograph, Australian passport, or Photo Card issued under the Photo Card Act 2005. Record ID details on the end user declaration and keep a copy for two years. Train staff to refuse or escalate sales where the buyer cannot produce one of the three specified documents (s 8).
• Written authorisations and access control for Schedule 1. If you authorise another person in writing to access stored Schedule 1 precursors, keep the written authorisation, make it available for inspection during business hours on request by a police officer, and retain a copy for at least two years after it ceases to have effect (s 5(3)). Implement locked storage that prevents unauthorised access (s 5(2)).
• Supply records. When supplying Schedule 1, 2 or 3 items, record the name and quantity of the item supplied and the date of supply from premises (ss 5(4), 6(2), 7(2)). Ensure logs are secure, indexed and backed up and that copies are available for police inspection.
• Compliance audits. Conduct regular internal audits to ensure records are complete, that end user declarations meet content requirements, and that proof-of-ID retention and storage rules are observed.

NSW Police Force members and exhibits managers

• Initial recording protocols. As soon as practicable after a relevant substance first comes into police custody and before any sample is taken, an approved member must record the initial mass or quantity or provide the substance to an analyst to do so. Produce a certificate of that initial quantity or mass and ensure a copy is served on the defendant in all proceedings relating to the substance (s 11(1)-(2)). Maintain forms and processes to generate and serve these certificates reliably.
• Drug exhibit bag procedures. Place every relevant substance into an approved drug exhibit bag as soon as practicable. Seal, label and sign the bag using the approved labelling method. Labels must include date and time sealed, registered exhibit number, name of alleged offender if known, name of the member in charge of the investigation, name of person who sealed the bag and signature (s 21). Prepare procedural checklists to ensure these fields are always completed.
• Storage security. Keep drug exhibit bags in a locked vault or cabinet with a dual locking mechanism requiring at least two separate keys, or in an approved facility when not in transit (s 23). Maintain key control records and logs of access to dual-key storage.
• Exhibits management system entries. Enter particulars of a relevant substance into the NSW Police Force exhibits management system as soon as practicable. Update the system with particulars of any occasion when a sealed bag is opened and particulars of any changes in identification details or location, including transport to analysts or qualified plant identifiers (s 24). Train staff to maintain integrity of system entries and to produce certified exhibit detail sheets when needed (s 31).
• Opening and inspection protocol. Open sealed drug exhibit bags only where permitted: for weighing, presumptive testing, or sampling, or with written approval of a qualified police officer or their delegate when exceptional circumstances justify earlier opening (s 22(1)). If opened prior to analysis, ensure opening is witnessed by at least two persons from the specified categories (s 22(2)). Document the opening and create a certificate as required by s 32.
• B sample requests. Receive and process B sample requests from defendants within the 28 day window and arrange for sufficient material to be provided to an analyst. Keep records demonstrating timely arrangements and service of B analysis results to both the qualified police officer and the defendant (s 16).
• Destruction processes. Before destruction ordered under Act Part 3A or Regulation, arrange inspection by a police officer of or above the rank of inspector to determine if the bag has been tampered with. Conduct destruction in the presence of the required persons (inspector, independent witness, member capable of identifying the exhibit) and retain certificates and photographic evidence as required by s 25 (ss 28-29, 25).

Analysts and FASS laboratories

• Sample receipt and authentication. On receiving a relevant substance for analysis, confirm the drug exhibit bag seal was intact when received and document condition as required in certificates under s 32(2)(c). Where there are differences between certificates, note whether the variation is significant and, if so, forward all certificates to the DPP immediately (s 19).
• A and B sample management. Retain required amounts: when practicable, the officer or analyst must retain the required amount of a relevant substance equal to three times the amount required for two samples (s 13). For substances above traffickable or commercial quantities, provide an A sample as soon as reasonably practicable and perform purity testing where appropriate and practicable (ss 14, 17(2)). On B sample requests, provide the required analysis and copy results to the qualified police officer and the defendant (s 16).
• Certificates. Prepare analyst certificates containing the matters specified in s 17 and consistent with the Act, s 43(1). Maintain secure signature and appointment records even though s 33 makes proof unnecessary for prima facie effect; these records are essential for internal quality assurance and potential judicial review (ss 17-18, 33).
• Sample destruction authorisations. Only destroy sample material when authorised by a director of FASS or a delegate under s 26(1), and follow witness and inspection requirements where destruction is under police authority (ss 26-29). Keep clear records of destruction orders, inspections and witnesses.

Couriers and contracted cannabis service providers

• Approved courier compliance. If transporting drug exhibit bags, ensure the bag is an approved tamper-evident bag and that you are an approved courier under police arrangements. Keep transport documentation showing the chain of custody and that transportation was in accordance with Act processes to rely on the exemption from possession or supply offences (s 20(2)-(3)).
• Contracted cannabis handlers. If engaged under police contract to transport, store or destroy cannabis, ensure your contract explicitly confines activities to those authorised and maintain records evidencing performance in accordance with the contract, since the exemption applies only to the extent necessary to perform contract duties (s 36).

Pharmacists, needle and syringe programs and public health actors

• Program list verification. Confirm that a needle and syringe program is specified in the Ministry of Health document entitled "Exempt Needle and Syringe Programs" published on 24 August 2021 if relying on the exemption in s 37. Keep documentation demonstrating program status, operating hours and client lists as appropriate.
• Pharmacy practice alignment. Pharmacists and supervised staff distributing syringes should ensure distribution and hygienic information are provided in the ordinary course of pharmacy practice and maintain records of clients served as appropriate to evidence that distribution fell within the exemption in s 38.

Defendants and defence counsel

• Timeliness for B requests. Note the 28 day deadline after service of the A sample certificate to request B sample analysis (s 16(3)). Prepare to act promptly on receipt of A sample certificates.
• Costs of B analysis. Be aware that the Regulation requires the defendant to pay the cost of B sample analysis (s 16(7)). Budget for this cost or seek variation through court if necessary.
• Quantity review orders. If challenging prima facie certificates, consider whether a quantity review order under Act, s 39M is available; if made, it displaces the prima facie effect of the certificate under s 11(4).

Operational controls and documentation

• Written procedures and staff training. All affected organisations should adopt written procedures that map Regulation requirements to operational steps, including who completes and signs which forms, how drug exhibit bags are sealed and logged, and how entries into the exhibits management system are performed.
• Audit trails and backups. Maintain secure, tamper-evident storage for physical evidence and robust digital audit trails for exhibits management system entries and supplier records. Retain backups for the two year statutory retention periods and longer where litigation or internal policy requires it.
• Interaction with other laws. Where exemptions rely on other statutes (for example therapeutic goods), maintain evidence of compliance with those regimes to rely on the exemptions (s 5(6)).

This compliance checklist derives directly from the Regulation’s operational provisions and is intended to translate statutory obligations into concrete organisational processes and records.